DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for purpura — screening already-approved drugs against its 18-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePurpura maps to a 18-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for purpura is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
serpin family C member 1 (SERPINC1) — SERPINC1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet z9ldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3KCG · 1.7 Å · ligand methyl 2,3,6-tri-O-sulfo-alpha-D-glucopyranoside (Z9L). Experimental structure, not a prediction.
What the evidence adds up to
Four patients developed purpuric eruptions after taking a carbromal-containing drug; the rash started on the ankles and spread to the upper legs, thighs, buttocks, and lower abdomen, accompanied by erythema, papules, and hemosiderosis, and was pruritic in each case. One patient showed cross-sensitivity with meprobamate, which caused the eruption to recur. The purpura was nonthrombocytopenic with a positive cuff test, and the eruption cleared two to four weeks after stopping the drug. Treatment was symptomatic.
For idiopathic thrombocytopenic purpura in adults, treatment is prescribed according to the clinical and haematological form, determined by special tests, and consists of corticotherapy, splenectomy in some cases, and immunosuppressive therapy in special cases. The first condition for accurate treatment is the correct diagnosis of idiopathic thrombocytopenic purpura, with elimination of secondary forms that require treatment of an etiological nature alongside treatment of the purpuric syndrome.
Purpura can be a manifestation of thrombocytopenia or vasculopathies; cutaneous vasculitis belongs to the latter group and should be considered a symptom rather than a medical entity. Some forms are limited to the skin, while others may be part of a systemic disease with a more serious prognosis. A delay in identification and start of treatment can cause serious and potentially irreversible complications.
In children with immune thrombocytopenic purpura, the review concludes that greater consensus on appropriate treatment strategies is needed to improve outcomes, and that ongoing research into pathogenesis is providing the basis for future treatment options. What is still missing is a unified treatment strategy for children, reliable stratification of isolated cutaneous vasculitis from systemic disease, and prospective trials that distinguish between drug-induced purpura and primary immune thrombocytopenia.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Archives of Dermatology · 1967 · 14 citations
Purpuric Eruptions Associated With Use of Carbromal and Meprobamate
AbstractPurpuric eruptions are reported in four patients, all of whom were taking a carbromal-containing drug. The eruption began on the ankles in each patient and then progressed to the upper legs, thighs, buttocks, and lower abdomen. In addition to the purpura, erythema, papules, and hemosiderosis were present. The eruption tended to be pruritic in each case. One of the patients presented showed a cross-sensitivity with meprobamate, which caused a recrudescence of the eruption. Patients with carbromal sensitivity characteristically have a nonthrombocytopenic purpura with a positive cuff test. Treatment is symptomatic, and the eruption tends to clear in two to four weeks after cessation of the drug.
International Journal for Research in Applied Science and Engineering Technology · 2024 · 0 citations · open access
Ways to Improve the Results of Treatment of Idiopathic Thrombocytopenic Purpura in Adults
AbstractAbstract: After long experience of various therapeutic attempts. Treatment of idiopathic thrombocytopenic purpura is prescribed in accordance with the clinical and hematological form, determined through special tests and consists, for curable forms, of corticotherapy, in some cases splenectomy and in special cases immunosuppressive therapy. The first condition for treatment with an accurate indication is the correct diagnosis of idiopathic thrombocytopenic purpura, with the elimination of secondary forms, which, along with the treatment of purpuric syndrome, require treatment of an etiological nature.
De la vasculite cutanée isolée aux atteintes systémiques : l’approche diagnostique d’un purpura chez l’adulte
AbstractPurpura can be a clinical manifestation of various diseases. The causes of purpura are divided into two main categories: thrombocytopenia and vasculopathies. Cutaneous vasculitis belongs to the latter group. Cutaneous vasculitis should be considered a symptom rather than a medical entity. Some forms of cutaneous vasculitis are limited to the skin and are known as isolated cutaneous vasculitis, while other forms may be part of a systemic disease with a more serious prognosis. It is essential to clarify the type and severity of the disease for optimal patient care. A delay in the identification and start of treatment can be the cause of serious and potentially irreversible complications. Through this article, we will propose a step-by-step approach from diagnosis to patient care.
East African Medical Journal · 2010 · 0 citations · open access
Managment of immune thrombocytopaenia in children: a review
AbstractOBJECTIVE: To provide an overview of the various treatment options available in the rational management of ITP in children. DATA SOURCE: Published original research findings and reviews. DATA SELECTION: On-line searches for published data on immune thrombocytopaenia, idiopathic thrombocytopaenia, thrombocytopaenic purpura. DATA EXTRACTION: Abstracts of selected articles were read and analysed to determine their relevance to this article. DATA SYNTHESIS: All relevant articles were read in full and necessary contribution extracted for this review. CONCLUSION: Immune thrombocytopaenic purpura is a common disorder affecting children and adults. Ongoing research into the pathogenesis is providing the basis for future treatment options. Greater consensus as to appropriate treatment strategies is needed to improve outcomes.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
